One MedImmune Way
15 articles with Viela Bio
Viela Bio Announces Data Presentations at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Viela Bio announced that data from the N-MOmentum trial—the largest global, placebo-controlled study conducted in patients with neuromyelitis optica spectrum disorder—have been selected for an oral plenary session presentation as well as poster presentations at the upcoming 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder
Viela Bio announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder.
Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder
Viela Bio announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for inebilizumab, an investigational anti-CD19 monoclonal antibody, for the treatment of patients with neuromyelitis optica spectrum disorder — a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.
Mr. Nolet brings more than 38 years of financial leadership experience in the Life Sciences industry.
7/3/2019Biotech and pharma companies strengthen their executive leadership and board positions.
Viela Bio announced the appointment of Mitchell Chan as Chief Financial Officer, effective July 1.
Funding to support regulatory filing and pre-commercial planning for lead product candidate, inebilizumab, and to advance development of additional clinical candidates targeting autoimmune and inflammatory diseases
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China
Viela Bio, Inc. and Hansoh Pharmaceutical Group Company Limited announced a collaboration focused on development and commercialization of inebilizumab – Viela’s humanized anti-CD19 monoclonal antibody – in China for neuromyelitis optica spectrum disorder, as well as other potential inflammation/autoimmune and hematologic malignancy indications.
Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting
Company to hold investor event on May 9th
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
Designation based on positive primary analysis of pivotal study, N-MOmentum
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Largest controlled monotherapy trial in NMOSD demonstrates reduction in risk of attacks and reduction in worsening of disability in patients treated with inebilizumab
Viela Bio, based in Gaithersburg, Md., announced that N-MOmentum, its Phase IIb pivotal trial of inebilizumab, met both primary and key secondary endpoints in neuromyelitis optica spectrum disorder (NMOSD).